NEW YORK ( TheStreet) -- CHANGE IN RATINGS AMC Networks ( AMCX) rated new Overweight at JP Morgan. $43 price target. Pullback has created an attractive buying opportunity in the growing company. Amazon.com ( AMZN) rated new Outperform at Morgan Keegan. $210 price target. Company can continue to gain market share in North America. Acme Packet ( APKT) rated new Neutral at JP Morgan. $29 price target. Inflection point in growth may still be several quarters away. Bill Barrett ( BBG) downgraded to hold at TheStreet Ratings. Biglari Holdings ( BH) downgraded to hold at TheStreet Ratings. Broadcom ( BRCM) upgraded at Wells from Market Perform to Outperform, Wells Fargo said. Valuation call, as earnings should rebound in 2012. Boston Scientific ( BSX) downgraded at Goldman to Sell, Goldman Sachs said. Consensus estimates appear too high. BorgWarner ( BWA) downgraded at UBS from Buy to Neutral, UBS said. $68 price target. Europe headwinds remain despite german OEM exposure. Deckers ( DECK) downgraded at Sterne Agee from Buy to Underperform, Sterne Agee said. Estimates also cut, following disappointing channel checks for UGG. $72 price target. First Solar ( FSLR) downgraded at Baird from Outperform to Neutral, Robert Baird said. $35 price target. Company slashed it guidance and the business is in a transition period. Forest Oil ( FST) rated new Hold at Keybanc. Company still has to show that it can generate growth in newer shale areas. Gulfport Energy ( GPOR) rated new Outperform at Credit Suisse. $41 price target. Utica shale should continue to drive growth. Hospira ( HSP) rated new Sell at UBS. $25 price target. Recovery from manufacturing issues could be slow. ITC ( ITC) upgraded at Deutsche from Hold to Buy, Deutsche Bank said. Company can deliver above-average growth in the coming quarters. $79 price target. Kior ( KIOR) upgraded at Baird from Underperform to Neutral, Robert Baird said. Valuation call, based on a $10 price target. Laboratory Corp. ( LH) downgraded at Goldman to Sell, Goldman Sachs said. Industry is facing flat volumes and rising costs. Lam Research ( LRCX) upgraded at Needham from Hold to Buy, Needham said. $46 price target. NVLS purchase will improve scale and customer leverage. PerkinElmer ( PKI) upgraded at Goldman to Buy, Goldman Sachs said. Sentiment appears to have bottomed out for the group.
Skyworks ( SWKS) downgraded at Deutsche from Buy to Hold, Deutsche Bank said. $22 price target. Stock appears oversold, following a 37% decline. Stryker ( SYK) downgraded at Goldman to Neutral, Goldman Sachs said. End-market demand remains weak. Teco Energy ( TE) upgraded at Deutsche from Sell to Hold, Deutsche Bank said. $17 price target. Company remains should continue to deliver solid growth in the coming quarters. Thermo Fisher ( TMO) rated new Outperform at Credit Suisse. $57 price target. Company can deliver consistent, double-digit earnings growth. Thermo Fisher downgraded at Goldman to Neutral, Goldman Sachs said. Valuation call. Waters ( WAT) rated new Neutral at Credit Suisse. Valuation call, based on an $80 price target. Zions Bancorporation ( ZION) downgraded at KBW from Outperform to Market Perform, KBW said. Stock will likely remain range-bound, until more details emerge about its capital plan in March. $19 price target.
STOCK COMMENTS / EPS CHANGESAgilent ( A) added to US Focus List at Credit Suisse. Company can deliver solid annual growth in the coming years and trades at a discount to the market. Abbott Laboratories ( ABT) numbers lowered at Citigroup. Shares of ABT now seen reaching $46, according to Citigroup. Estimates also lowered as DMP sales targets look unrealistic. Sell rating. Baxter ( BAX) cut from Conviction Buy List at Goldman. Company lacks near-term catalysts. Broadcom ( BRCM) estimates raised at UBS through 2012, UBS said. Revises sales outlook to high end on better mobile and wireless demand. ConAgra Foods ( CAG) estimates raised at Jefferies through 2012, Jefferies said. New $750 million share buyback authorization. Hold rating. Crown Holdings ( CCK) numbers raised at Credit Suisse. Shares of CCK now seen reaching $44, according to Credit Suisse. Estimates also increased, as the company is buying back more stock. Outperform rating. Carnival ( CCL) estimates lowered at Goldman through 2013, Goldman Sachs said. Company is facing higher fuel prices. Buy rating and $41 price target. Delta Air Lines ( DAL) estimates lowered at UBS through 2012, UBS said. Higher non-fuel costs. Maintain $12 price target and Buy rating. DuPont ( DD) target reduced at Credit to $50, according to Credit Suisse. Company faces near-term growth headwinds. Neutral rating.
Danaher ( DHR) estimates lowered at UBS through 2012 on macro challenges, UBS said. Maintain $58 price target and Buy rating. E*Trade ( ETFC) estimates lowered at Goldman through 2012, Goldman Sachs said. Company is seeing lower trading activity. FactSet Research Systems ( FDS) estimates lowered at Oppenheimer through 2012, Oppenheimer said. User growth seeing some pressure. Perform rating. First Solar ( FSLR) numbers lowered at Jefferies. Shares of FSLR now seen reaching $38, Jefferies said. Estimates also lowered on terrible end market conditions. Hold rating. First Solar numbers cut at Credit Suisse. Shares of FSLR now seen reaching $30, according to Credit Suisse. Estimates also reduced, given lower systems profitability. Neutral rating. First Solar numbers lowered at UBS. Shares of FSLR now seen reaching $36, according to UBS. Estimates also lowered as new strategy could take 2-3 years to implement. Corning ( GLW) estimates increased at Morgan Stanley through 2013, Morgan Stanley said. Expect lower prices to drive TV demand. Equal-weight rating. GrafTech International ( GTI) numbers lowered at Jefferies. Shares of GTI now seen reaching $23, Jefferies said. Estimates also lowered on European electric market uncertainty. Buy rating. Knight Capital ( KCG) numbers cut at Goldman. Shares of KCG now seen reaching $13, according to Goldman Sachs. Estimates also reduced, given slower core trading activity. Buy rating. Lowe's ( LOW) target boosted at Morgan Stanley. Shares of LOW now seen reaching $23, according to Morgan Stanley. Company has improved clarity on potential margin expansion. Underweight rating. Novellus Systems ( NVLS) target raised at UBS to $44, according to UBS. Lam's offfer to acquire company at 28% premium. Neutral rating. Onyx Pharmaceuticals ( ONXX) added to Conviction Buy List at Goldman. Company should report lots of positive data in the coming quarters. VeriFone Systems ( PAY) numbers raised at Citigroup. Shares of PAY now seen reaching $53, according to Citigroup. Company raised guidance to account for pending Point acquisition. Buy rating. Charles Schwab ( SCHW) numbers cut at Goldman. SCHW estimates were reduced through 2013, Goldman Sachs said. Net interest margins and trading activity are declining. New $12 price target. ViroPharma ( VPHM) numbers raised at Oppenheimer. Shares of VPHM now seen reaching $32, Oppenheimer said. Estimates also raised as generic overhang is removed. Outperform rating. ViroPharma estimates, target boosted at JMP. Shares of VPHM now seen reaching $35, according to JMP Securities. Estimates also upped, given higher expected Vancocin sales. Outperform rating. ViroPharma numbers raised at Jefferies. Shares of VPHM now seen reaching $33, Jefferies said. Estimates also raised on approval of a new label for Vancocin. Buy rating. >To submit a news tip, email: firstname.lastname@example.org.
Twitter and become a fan on Facebook.
Twitter and become a fan on Facebook.